F Perraud
Overview
Explore the profile of F Perraud including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Braun S, Thioudellet C, Perraud F, Escriou C, Claudepierre M, Homann H, et al.
Cytotechnology
. 2008 Nov;
30(1-3):181-9.
PMID: 19003368
We have developed and characterized cultures of healthy and dystrophic canine myoblasts for the evaluation of various gene transfer protocols. The number of desmin-positive myoblasts was elevated (>>80%) in cultures...
2.
Braun S, Thioudellet C, Rodriguez P, Perraud F, Accart N, Balloul J, et al.
Gene Ther
. 2000 Sep;
7(17):1447-57.
PMID: 11001364
Intramuscular administration of plasmid expressing full-length human dystrophin in dystrophin-deficient adult mdx mice resulted in humoral and weak specific T cell responses against the human dystrophin protein. Following plasmid injection,...
3.
Schughart K, Bischoff R, Rasmussen U, Hadji D, Perraud F, Accart N, et al.
Hum Gene Ther
. 1999 Dec;
10(18):2891-905.
PMID: 10609651
A novel type of synthetic vector, termed solvoplex, is described that can greatly enhance gene expression in lung after intrapulmonary delivery. Solvoplexes consist of plasmid DNA and organic solvents. Several...
4.
Schughart K, Bischoff R, Hadji D, Boussif O, Perraud F, Accart N, et al.
Gene Ther
. 1999 Aug;
6(3):448-53.
PMID: 10435095
One of the main limitations for the use of synthetic vectors in gene therapy is their relatively low in vivo efficiency when compared with viral vectors. Here, we describe a...
5.
Braun S, Jenny C, Thioudellet C, Perraud F, Claudepierre M, Schughart K, et al.
FEBS Lett
. 1999 Aug;
454(3):277-82.
PMID: 10431822
As a pharmacological approach to potentially improve gene transfer efficiency into skeletal muscle cells, glucocorticoids were shown here to allow efficient transfection of cultured and mouse human myoblasts, human pulmonary...
6.
Bischoff R, Cordier Y, Perraud F, Thioudellet C, Braun S, Pavirani A
Anal Biochem
. 1998 Jan;
254(1):69-81.
PMID: 9398348
Transfection of satellite cells from dog muscle (myoblasts) in primary culture has been optimized with respect to the position of the cholesteryl moiety along the polyamine chain of spermidine or...
7.
Bellon G, Michel-Calemard L, Thouvenot D, Jagneaux V, Poitevin F, Malcus C, et al.
Hum Gene Ther
. 1997 Jan;
8(1):15-25.
PMID: 8989991
Ad CFTR, a replication-deficient adenovirus expressing the human cystic fibrosis transmembrane conductance regulator (CFTR), was administered by aerosolization in a single escalating dose to three pairs (cohorts) of cystic fibrosis...
8.
Bellon G, Calmard L, Thouvenot D, Levrey H, Jagneaux V, Poitevin F, et al.
C R Seances Soc Biol Fil
. 1996 Jan;
190(1):109-42.
PMID: 8881273
At present it is conceivable to think that gene therapy represents a way to treat or even prevent the respiratory manifestations of cystic fibrosis. Consistent to such a concept, there...
9.
Bischoff R, Degryse E, Perraud F, Dalemans W, Thepot D, Devinoy E, et al.
FEBS Lett
. 1992 Jul;
305(3):265-8.
PMID: 1299629
We have investigated whether DNA regions present in the rabbit whey acidic protein (WAP) promoter/5' flanking sequence could potentially confer, in vivo, high level expression of reporter genes. Transgenic mice...
10.
Perraud F, Yoshimura K, Louis B, Dalemans W, Schultz H, Claudepierre M, et al.
Oncogene
. 1992 May;
7(5):993-7.
PMID: 1373882
Transgenic mice bearing a human cystic fibrosis transmembrane conductance regulator (CFTR) promoter-SV40 T antigen fusion transgene were generated in order to localize in vivo the potential oncogenesis linked to the...